¼¼°èÀÇ ·Î»ç¸£Åº Ä®·ý ¿ø·áÀǾàǰ(API) ½ÃÀå º¸°í¼­(2025³â)
Losartan Potassium Active Pharmaceutical Ingredient (API) Global Market Report 2025
»óǰÄÚµå : 1760599
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,217,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,987,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,756,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

·Î»ìź Ä®·ý ¿ø·áÀǾàǰ(API) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̸ç 2029³â±îÁö 6.9%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü·Î 24¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ¸¸¼ºÁúȯÀ» ¾Î°í Àִ ȯÀÚ Àα¸ÀÇ Áõ°¡, ½ÉÇ÷°ü°è ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÇコÄÉ¾î ¼­ºñ½º º¸±Þ È®´ë, Á¦Çü ±â¼ú ¹ßÀü, Á¦³×¸¯ ÀǾàǰÀ» Àå·ÁÇÏ´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºêÀÇ Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£ µ¿¾È ¼±Áø ÆÐŰ¡ Æ®·»µå¿¡´Â Á¦Á¶ °øÁ¤ÀÇ ¹ßÀü, ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ °³¹ß, ¼Ò¾Æ¿¡ ÀûÇÕÇÑ Á¦Çü °³¹ß, À¯Åë±âÇÑ ¿¬ÀåÀ» À§ÇÑ ÆÐŰ¡ ±â¼ú Çõ½Å, ·Î»ìźÀ» Æ÷ÇÔÇÑ º´¿ë¿ä¹ý °³¹ß µîÀÌ Æ÷ÇԵ˴ϴÙ.

°íÇ÷¾Ð À¯º´·üÀÇ Áõ°¡´Â ·Î»ìź Ä®·ý ¿ø·áÀǾàǰ(API) ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °íÇ÷¾ÐÀº Áö¼ÓÀûÀÎ °íÇ÷¾ÐÀ» Ư¡À¸·Î ÇÏ´Â ÁúȯÀ¸·Î ½ÉÀ庴, ³úÁ¹Áß ¹× ±âŸ ½É°¢ÇÑ °Ç°­ ÇÕº´ÁõÀÇ À§ÇèÀ» Áõ°¡½Ãŵ´Ï´Ù. °íÇ÷¾Ð ¹ßº´·üÀÇ Áõ°¡´Â ¼Ò±Ý°ú °¡°ø½ÄǰÀÌ ¸¹Àº ½Ä½À°üÀÌ Ã¼¾× Àú·ù¿Í ½ÉÀåÀÇ ºÎ´ãÀ» Áõ°¡½ÃŰ´Â ÁÖ¿ä ¿øÀÎÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ·Î»ìźĮ·ýÀº Ç÷°üÀ» ¼öÃà½ÃŰ´Â È£¸£¸óÀÎ ¾ÈÁö¿ÀÅٽŠII¸¦ ¾ïÁ¦ÇÏ¿© °íÇ÷¾ÐÀ» ¾ïÁ¦ÇÕ´Ï´Ù. Ç÷°üÀ» À̿ϽÃ۰í È®Àå½ÃÅ´À¸·Î½á ·Î»ìź Ä®·ýÀº Ç÷¾ÐÀ» ³·Ãß°í ½ÉÀåÀÇ ºÎ´ãÀ» ÁÙÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù ¹Ì±¹½ÉÀåÇùȸ´Â 2022³â ÁÖ¿ä °íÇ÷¾Ð °ü·Ã »ç¸ÁÀÚ ¼ö°¡ 13¸¸ 1,454¸íÀ¸·Î 2021³â 12¸¸ 4,508¸í¿¡¼­ Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. °á°úÀûÀ¸·Î °íÇ÷¾Ð À¯º´·üÀÇ Áõ°¡´Â ·Î»ìź Ä®·ý API ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

·Î»ç¸£Åº Ä®·ý API ½ÃÀåÀÇ ±â¾÷µéÀº ·Î»ç¸£Åº Ä®·ý °æ±¸ Çöʾװú °°ÀÌ È¯ÀÚÀÇ ¼øÀÀµµ¿Í Åõ¾à Á¤È®µµ¸¦ ³ôÀÌ´Â Çõ½ÅÀûÀÎ Á¦Ç° °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¾×ü ÇüÅÂÀÇ ·Î»ìź Ä®·ýÀº Á¤Á¦¸¦ »ïŰ±â ¾î·Á¿î ȯÀÚ¸¦ À§ÇØ ¼³°èµÇ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 3¿ù ¹Ì±¹ ¹ÙÀÌ¿À Á¦¾à»ç »çÀ̾𽺠Ȧµù½º(Science Holdings Inc.)´Â °íÇ÷¾Ð Ä¡·á, ÁÂ½É½Ç ºñ´ëÁõÀ» µ¿¹ÝÇÑ °íÇ÷¾Ð ȯÀÚÀÇ ³úÁ¹Áß À§Çè °¨¼Ò, Á¦2Çü ´ç´¢º´ ȯÀÚÀÇ ´ç´¢º´¼º ½ÅÁõ¿¡ ´ëÇÑ ÀûÀÀÁõÀ¸·Î Áï½Ã »ç¿ë °¡´ÉÇÑ ¾×»ó Á¦Á¦ÀÎ ArbliÀÇ FDA ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. Arbli´Â 165mLÀÇ ÆäÆÛ¹ÎÆ® ÇâÀÌ ³ª´Â Çöʾ×(10mg/mL)À¸·Î, ½Ç¿Â¿¡¼­ 18°³¿ù µ¿¾È º¸°üÇÒ ¼ö ÀÖÀ¸¸ç, ¹èÇÕÁ¦°¡ ÇÊ¿ä ¾ø´Â Á¤È®ÇÑ Åõ¾àÀÌ °¡´ÉÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå °Å½Ã°æÁ¦ ½Ã³ª¸®¿À : ±Ý¸®¡¤ÀÎÇ÷¹À̼ǡ¤ÁöÁ¤ÇС¤¹«¿ª ÀüÀ°ü¼¼¡¤Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ´Ù

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå : °æÀï º¥Ä¡¸¶Å·¡¤´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ±â¾÷ ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·Â ³ôÀº ³ª¶ó¡¤ºÎ¹®°ú Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Losartan potassium active pharmaceutical ingredient (API) refers to the pure compound used in the formulation of losartan-based medications, which are primarily used to treat high blood pressure and protect kidney function. It mainly helps manage hypertension, reduces the risk of heart attacks, and preserves kidney function in diabetic patients.

The main product forms of losartan potassium API include tablets, capsules, and others. Tablets are the most commonly used oral form, valued for their ease of use, affordability, and precise dosing in managing hypertension. It is produced through various methods such as synthetic routes, biotechnological processes, and continuous flow production. Distribution channels include online pharmacies, hospital pharmacies, retail pharmacies, and others. Losartan potassium is used for a range of conditions, including hypertension, heart failure, chronic kidney disease, and more. It is employed by various end-users, such as hospitals, clinics, home care settings, and pharmaceutical companies.

The losartan potassium API market research report is one of a series of new reports from The Business Research Company that provides losartan potassium API market statistics, including the losartan potassium API industry global market size, regional shares, competitors with the losartan potassium API market share, detailed losartan potassium API market segments, market trends, and opportunities, and any further data you may need to thrive in the losartan potassium API industry. This losartan potassium API market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The losartan potassium active pharmaceutical ingredient (API) market size has grown strongly in recent years. It will grow from $1.75 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to factors such as the growing adoption of antihypertensive drugs, the rising incidence of lifestyle-related disorders, increased awareness of cardiovascular health, higher global healthcare expenditure, and the growing demand for affordable generic medications.

The losartan potassium active pharmaceutical ingredient (API) market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period can be attributed to factors such as an expanding patient population with chronic illnesses, a growing emphasis on preventive cardiovascular care, increased healthcare service penetration in emerging markets, advancements in drug formulation technologies, and rising government initiatives to promote generic drugs. Key trends during this period include advancements in manufacturing processes, the development of advanced drug delivery systems, the creation of pediatric-friendly formulations, innovations in packaging for extended shelf life, and the development of combination therapies involving losartan.

The rising prevalence of hypertension is expected to drive the growth of the losartan potassium active pharmaceutical ingredient (API) market. Hypertension is a condition characterized by persistently high blood pressure, which increases the risk of heart disease, stroke, and other serious health complications. The growing incidence of hypertension is largely attributed to diets high in salt and processed foods, which contribute to fluid retention and increased strain on the heart. Losartan potassium helps control hypertension by blocking angiotensin II, a hormone that constricts blood vessels. By relaxing and widening blood vessels, losartan potassium lowers blood pressure and reduces the workload on the heart. For instance, in January 2024, the American Heart Association reported that 131,454 deaths were primarily linked to high blood pressure in 2022, a rise from 124,508 deaths in 2021. As a result, the increasing prevalence of hypertension is fueling the growth of the losartan potassium API market.

Companies in the losartan potassium API market are focusing on developing innovative products to enhance patient compliance and precision in dosing, such as losartan potassium oral suspension. This liquid form of losartan potassium is designed for patients who have difficulty swallowing tablets. For example, in March 2025, Scienture Holdings Inc., a US-based biopharmaceutical company, received FDA approval for Arbli, a ready-to-use liquid formulation for hypertension treatment, stroke risk reduction in hypertensive patients with left ventricular hypertrophy, and diabetic nephropathy in type 2 diabetes patients. Arbli offers precise dosing without the need for compounding and comes in a 165 mL peppermint-flavored suspension (10 mg/mL) with an 18-month shelf life at room temperature.

In April 2025, Scienture Holdings Inc., a US-based pharmaceutical company, formed a partnership with Saptalis Pharmaceuticals LLC to manufacture Arbli (losartan potassium) Oral Suspension, 10 mg/mL. The collaboration includes warehousing and distribution agreements to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in hypertension treatment. Saptalis Pharmaceuticals LLC, a US-based pharmaceutical company, specializes in developing and distributing losartan potassium formulations.

Major players in the losartan potassium active pharmaceutical ingredient (API) market are Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories, Cadila Pharmaceuticals Ltd, Lupin Ltd, Zydus Lifesciences Ltd, Alkem Laboratories Ltd, IPCA Laboratories Ltd, Alembic Pharmaceuticals Ltd, Granules India Limited, Vasudha Pharma Chem Ltd, IOL Chemicals and Pharmaceuticals Limited, Unichem Laboratories Ltd, Global Pharma Tek, Hetero Drugs Ltd, Manus Aktteva Biopharma LLP, Wellona Pharma, Atom pharma, Sinoway Industrial Co. Ltd, Cerata Pharmaceuticals LLP.

North America was the largest region in the losartan potassium API market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in losartan potassium active pharmaceutical ingredient (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the losartan potassium active pharmaceutical ingredient (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The losartan potassium active pharmaceutical ingredient (API) market consists of sales of bulk powder, granules, injectable concentrates, and pre-formulated intermediates. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Losartan Potassium Active Pharmaceutical Ingredient (API) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on losartan potassium active pharmaceutical ingredient (api) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for losartan potassium active pharmaceutical ingredient (api) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The losartan potassium active pharmaceutical ingredient (api) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Losartan Potassium Active Pharmaceutical Ingredient (API) Market Characteristics

3. Losartan Potassium Active Pharmaceutical Ingredient (API) Market Trends And Strategies

4. Losartan Potassium Active Pharmaceutical Ingredient (API) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Losartan Potassium Active Pharmaceutical Ingredient (API) Growth Analysis And Strategic Analysis Framework

6. Losartan Potassium Active Pharmaceutical Ingredient (API) Market Segmentation

7. Losartan Potassium Active Pharmaceutical Ingredient (API) Market Regional And Country Analysis

8. Asia-Pacific Losartan Potassium Active Pharmaceutical Ingredient (API) Market

9. China Losartan Potassium Active Pharmaceutical Ingredient (API) Market

10. India Losartan Potassium Active Pharmaceutical Ingredient (API) Market

11. Japan Losartan Potassium Active Pharmaceutical Ingredient (API) Market

12. Australia Losartan Potassium Active Pharmaceutical Ingredient (API) Market

13. Indonesia Losartan Potassium Active Pharmaceutical Ingredient (API) Market

14. South Korea Losartan Potassium Active Pharmaceutical Ingredient (API) Market

15. Western Europe Losartan Potassium Active Pharmaceutical Ingredient (API) Market

16. UK Losartan Potassium Active Pharmaceutical Ingredient (API) Market

17. Germany Losartan Potassium Active Pharmaceutical Ingredient (API) Market

18. France Losartan Potassium Active Pharmaceutical Ingredient (API) Market

19. Italy Losartan Potassium Active Pharmaceutical Ingredient (API) Market

20. Spain Losartan Potassium Active Pharmaceutical Ingredient (API) Market

21. Eastern Europe Losartan Potassium Active Pharmaceutical Ingredient (API) Market

22. Russia Losartan Potassium Active Pharmaceutical Ingredient (API) Market

23. North America Losartan Potassium Active Pharmaceutical Ingredient (API) Market

24. USA Losartan Potassium Active Pharmaceutical Ingredient (API) Market

25. Canada Losartan Potassium Active Pharmaceutical Ingredient (API) Market

26. South America Losartan Potassium Active Pharmaceutical Ingredient (API) Market

27. Brazil Losartan Potassium Active Pharmaceutical Ingredient (API) Market

28. Middle East Losartan Potassium Active Pharmaceutical Ingredient (API) Market

29. Africa Losartan Potassium Active Pharmaceutical Ingredient (API) Market

30. Losartan Potassium Active Pharmaceutical Ingredient (API) Market Competitive Landscape And Company Profiles

31. Losartan Potassium Active Pharmaceutical Ingredient (API) Market Other Major And Innovative Companies

32. Global Losartan Potassium Active Pharmaceutical Ingredient (API) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Losartan Potassium Active Pharmaceutical Ingredient (API) Market

34. Recent Developments In The Losartan Potassium Active Pharmaceutical Ingredient (API) Market

35. Losartan Potassium Active Pharmaceutical Ingredient (API) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â